Share-based Payment Arrangement, Expense in USD of ATOSSA THERAPEUTICS, INC. from 2012 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
ATOSSA THERAPEUTICS, INC. quarterly/annual Share-based Payment Arrangement, Expense history and change rate from 2012 to Q3 2025.
  • ATOSSA THERAPEUTICS, INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $784K, a 4.67% increase year-over-year.
  • ATOSSA THERAPEUTICS, INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $2.92M, a 43.2% increase year-over-year.
  • ATOSSA THERAPEUTICS, INC. annual Share-based Payment Arrangement, Expense for 2024 was $2.29M, a 50.4% decline from 2023.
  • ATOSSA THERAPEUTICS, INC. annual Share-based Payment Arrangement, Expense for 2023 was $4.62M, a 31.9% decline from 2022.
  • ATOSSA THERAPEUTICS, INC. annual Share-based Payment Arrangement, Expense for 2022 was $6.79M, a 28.9% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

ATOSSA THERAPEUTICS, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $2.92M $784K +$35K +4.67% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025
Q2 2025 $2.88M $796K +$444K +126% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025
Q1 2025 $2.44M $563K +$146K +35% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025
Q4 2024 $2.29M $774K +$255K +49.1% 01 Oct 2024 31 Dec 2024 10-K 25 Mar 2025
Q3 2024 $2.04M $749K -$177K -19.1% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025
Q2 2024 $2.21M $352K -$1.25M -78% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025
Q1 2024 $3.47M $417K -$1.16M -73.5% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025
Q4 2023 $4.62M $519K -$1.03M -66.4% 01 Oct 2023 31 Dec 2023 10-K 25 Mar 2025
Q3 2023 $5.65M $926K -$740K -44.4% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024
Q2 2023 $6.39M $1.6M -$168K -9.49% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024
Q1 2023 $6.56M $1.57M -$233K -12.9% 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024
Q4 2022 $6.79M $1.55M -$74K -4.57% 01 Oct 2022 31 Dec 2022 10-K 01 Apr 2024
Q3 2022 $6.86M $1.67M -$128K -7.14% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023
Q2 2022 $6.99M $1.77M +$557K +45.9% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023
Q1 2022 $6.43M $1.81M +$1.17M +182% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023
Q4 2021 $5.27M $1.62M +$988K +157% 01 Oct 2021 31 Dec 2021 10-K 22 Mar 2023
Q3 2021 $4.28M $1.79M +$1.13M +170% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022
Q2 2021 $3.15M $1.21M +$178K +17.1% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022
Q1 2021 $2.97M $640K -$47.8K -6.94% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022
Q4 2020 $3.02M $631K -$125K -16.5% 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2022
Q3 2020 $3.14M $664K -$88.1K -11.7% 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021
Q2 2020 $3.23M $1.04M -$4.28M -80.5% 01 Apr 2020 30 Jun 2020 10-Q 13 Aug 2021
Q1 2020 $7.51M $688K +$412K +149% 01 Jan 2020 31 Mar 2020 10-Q 14 May 2021
Q4 2019 $7.1M $756K 01 Oct 2019 31 Dec 2019 10-K 31 Mar 2021
Q3 2019 $752K +$420K +126% 01 Jul 2019 30 Sep 2019 10-Q 13 Nov 2020
Q2 2019 $5.32M +$5.14M +2871% 01 Apr 2019 30 Jun 2019 10-Q 13 Aug 2020
Q1 2019 $276K 01 Jan 2019 31 Mar 2019 10-Q 13 May 2020
Q3 2018 $332K +$108K +48.1% 01 Jul 2018 30 Sep 2018 10-Q 13 Nov 2019
Q2 2018 $179K -$2.36K -1.3% 01 Apr 2018 30 Jun 2018 10-Q 13 Aug 2019
Q4 2017 $787K $226K +$25.00 +0.01% 01 Oct 2017 31 Dec 2017 10-K 28 Mar 2019
Q3 2017 $787K $224K -$33.1K -12.9% 01 Jul 2017 30 Sep 2017 10-Q 13 Nov 2017
Q2 2017 $820K $181K -$18.8K -9.38% 01 Apr 2017 30 Jun 2017 10-Q 14 Aug 2017
Q1 2017 $838K $155K -$37.8K -19.6% 01 Jan 2017 31 Mar 2017 10-Q 11 May 2017
Q4 2016 $876K $226K +$58K +34.5% 01 Oct 2016 31 Dec 2016 10-K 08 Mar 2018
Q3 2016 $818K $257K -$60.6K -19.1% 01 Jul 2016 30 Sep 2016 10-Q 13 Nov 2017
Q2 2016 $879K $200K -$4.93K -2.4% 01 Apr 2016 30 Jun 2016 10-Q 14 Aug 2017
Q1 2016 $884K $192K +$43.6K +29.3% 01 Jan 2016 31 Mar 2016 10-Q 11 May 2017
Q4 2015 $840K $168K +$157K +1405% 01 Oct 2015 31 Dec 2015 10-K/A 21 Mar 2017
Q3 2015 $683K $318K +$171K +116% 01 Jul 2015 30 Sep 2015 10-Q/A 21 Mar 2017
Q2 2015 $513K $205K +$37.6K +22.4% 01 Apr 2015 30 Jun 2015 10-Q/A 21 Mar 2017
Q1 2015 $475K $149K -$81.3K -35.3% 01 Jan 2015 31 Mar 2015 10-Q/A 21 Mar 2017
Q4 2014 $556K $11.2K 01 Oct 2014 31 Dec 2014 10-K 30 Mar 2016
Q3 2014 $147K 01 Jul 2014 30 Sep 2014 10-Q 12 Nov 2015
Q2 2014 $168K 01 Apr 2014 30 Jun 2014 10-Q 06 Aug 2015
Q1 2014 $230K 01 Jan 2014 31 Mar 2014 10-Q 13 May 2015

ATOSSA THERAPEUTICS, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $2.29M -$2.33M -50.4% 01 Jan 2024 31 Dec 2024 10-K 25 Mar 2025
2023 $4.62M -$2.17M -31.9% 01 Jan 2023 31 Dec 2023 10-K 25 Mar 2025
2022 $6.79M +$1.52M +28.9% 01 Jan 2022 31 Dec 2022 10-K 01 Apr 2024
2021 $5.27M +$2.25M +74.5% 01 Jan 2021 31 Dec 2021 10-K 22 Mar 2023
2020 $3.02M -$4.08M -57.5% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2022
2019 $7.1M +$6.05M +574% 01 Jan 2019 31 Dec 2019 10-K 31 Mar 2021
2018 $1.05M +$267K +33.9% 01 Jan 2018 31 Dec 2018 10-K 26 Mar 2020
2017 $787K -$89.6K -10.2% 01 Jan 2017 31 Dec 2017 10-K 28 Mar 2019
2016 $876K +$36.1K +4.3% 01 Jan 2016 31 Dec 2016 10-K 08 Mar 2018
2015 $840K +$284K +51% 01 Jan 2015 31 Dec 2015 10-K/A 21 Mar 2017
2014 $556K -$887K -61.5% 01 Jan 2014 31 Dec 2014 10-K 30 Mar 2016
2013 $1.44M $0 0% 01 Jan 2013 31 Dec 2013 10-K 30 Mar 2015
2012 $1.44M 01 Jan 2012 31 Dec 2012 10-K 27 Mar 2014
* An asterisk sign (*) next to the value indicates that the value is likely invalid.